• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amazon Web Services Focuses On The Future, Anticipating AI Challenges Years In Advance To Deliver 'True Value' For Customers

    7/1/24 5:47:47 PM ET
    $AMZN
    $PFE
    Catalog/Specialty Distribution
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMZN alert in real time by email

    Amazon.com Inc (NASDAQ:AMZN) is taking an all-encompassing approach to enterprise AI in an effort to better deliver the tools that customers need when they need them.

    What To Know: Monday on CNBC’s “Closing Bell: Overtime,” Amazon Web Services (AWS) CEO Matt Garman stressed that there is so much more to AI than the chatbots which get most of the attention.

    “It’s not just one application, it’s not just a chatbot that you can put on your website and have talk to your customers, which is a very cool application by the way, but many customers if they stop there, they’re not going to get the true value out of what this technology is bringing to them,” Garman said.

    Amazon offers much more than just chatbot capabilities. AWS provides a set of services that help customers set up guardrails to build safe AI applications, combine multiple large language models together for optimal performance, index enterprise data to build sources of truth for answering questions and more, he explained.

    Amazon has a diverse customer set using AWS and Amazon’s AI technology to help perform a wide range of tasks. Pfizer Inc (NYSE:PFE), for example, is using generative AI through AWS and Bedrock for drug discovery, Garman said, adding that the company recently estimated that AWS would save them $1 billion this year as they work towards finding and building new drug offerings.

    According to Amazon’s website, Bedrock offers a choice of high-performing foundation models from leading AI companies through a single API, as well as a broad set of capabilities needed to build generative AI applications responsibly.

    Related Link: Amazon Sidesteps Jeff Bezos-Backed Carbon Offset Standard, Throws Hands Behind New Framework

    New reports surfaced this week suggesting Amazon could spend about $1 billion building out its AI offerings this year. When asked about the costs, Garman told CNBC that Amazon has a massive advantage over the competition because it has experience cutting costs at scale.

    Amazon has been working on AI for years as the company is always looking ahead to what will come next and that hasn’t slowed down, the AWS CEO said.

    “We have teams who think about three, five, seven years down the road, what are our power footprints going to need? How do we make sure that we have enough? And the volumes are getting to be such that that’s a thing that we need to think about,” Garman said.

    “AWS and Amazon overall has been the largest purchaser of renewable energy for the last several years in the world because we focus on how do we think ahead … we think about the same with regards to supply chain, we think about the same with regards to working with many of our partners. We think about memory, we think about storage, we think about processors, we think about networking — all of those pieces are super important for us so that customers don’t have to worry about it.”

    AMZN Price Action: Amazon shares closed Monday up 2.04% at $197.20, according to Benzinga Pro.

    Read Next:

    • Top Performing Industry ETFs In June: Software Leads Returns, Chipmakers Attract Most Inflows

    Photo: Shutterstock.

    Get the next $AMZN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMZN
    $PFE

    CompanyDatePrice TargetRatingAnalyst
    Pfizer Inc.
    $PFE
    2/20/2026$25.00Underweight
    Barclays
    Pfizer Inc.
    $PFE
    2/12/2026$27.00Outperform → Neutral
    Daiwa Securities
    Amazon.com Inc.
    $AMZN
    2/6/2026$300.00 → $280.00Buy
    Monness Crespi & Hardt
    Amazon.com Inc.
    $AMZN
    2/6/2026$175.00Buy → Neutral
    DA Davidson
    Amazon.com Inc.
    $AMZN
    2/2/2026$300.00 → $315.00Mkt Outperform
    Citizens JMP
    Amazon.com Inc.
    $AMZN
    1/28/2026$305.00 → $315.00Outperform
    Oppenheimer
    Amazon.com Inc.
    $AMZN
    1/28/2026$303.00 → $308.00Overweight
    KeyBanc Capital Markets
    Amazon.com Inc.
    $AMZN
    1/27/2026$295.00 → $300.00Buy
    Stifel
    More analyst ratings

    $AMZN
    $PFE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Pfizer with a new price target

    Barclays initiated coverage of Pfizer with a rating of Underweight and set a new price target of $25.00

    2/20/26 8:25:15 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer downgraded by Daiwa Securities with a new price target

    Daiwa Securities downgraded Pfizer from Outperform to Neutral and set a new price target of $27.00

    2/12/26 7:23:25 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Monness Crespi & Hardt reiterated coverage on Amazon with a new price target

    Monness Crespi & Hardt reiterated coverage of Amazon with a rating of Buy and set a new price target of $280.00 from $300.00 previously

    2/6/26 8:23:18 AM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    $AMZN
    $PFE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Blaylock Ronald E bought $499,072 worth of shares (19,457 units at $25.65), increasing direct ownership by 236% to 27,707 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    2/14/25 5:16:36 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Gottlieb Scott bought $28,240 worth of shares (1,000 units at $28.24), increasing direct ownership by 11% to 10,000 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    10/31/24 4:06:54 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gottlieb Scott bought $79,401 worth of shares (3,000 units at $26.47), increasing direct ownership by 50% to 9,000 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    12/19/23 9:31:01 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMZN
    $PFE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Worldwide Amazon Stores Herrington Douglas J converted options into 11,959 shares and sold $948,990 worth of shares (4,784 units at $198.37), increasing direct ownership by 1% to 512,109 units (SEC Form 4)

    4 - AMAZON COM INC (0001018724) (Issuer)

    2/18/26 6:16:06 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    Director Gorelick Jamie S converted options into 2,677 shares, increasing direct ownership by 7% to 40,794 units (SEC Form 4)

    4 - AMAZON COM INC (0001018724) (Issuer)

    2/18/26 6:05:51 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    Director Weeks Wendell P converted options into 1,816 shares, increasing direct ownership by 4% to 46,216 units (SEC Form 4)

    4 - AMAZON COM INC (0001018724) (Issuer)

    2/18/26 5:57:32 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    $AMZN
    $PFE
    SEC Filings

    View All

    SEC Form 13F-HR filed by Pfizer Inc.

    13F-HR - PFIZER INC (0000078003) (Filer)

    2/12/26 4:22:51 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 13F-HR filed by Amazon.com Inc.

    13F-HR - AMAZON COM INC (0001018724) (Filer)

    2/10/26 4:13:45 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    SEC Form S-3ASR filed by Amazon.com Inc.

    S-3ASR - AMAZON COM INC (0001018724) (Filer)

    2/6/26 7:38:34 AM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    $AMZN
    $PFE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 11, 2025 - FDA Roundup: March 11, 2025

    For Immediate Release: March 11, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:Today, the FDA published a General Correspondence Letter issued to Mid-Link Technology Testing Co., Ltd. The FDA is vigilant in ensuring data submitted to the FDA can be relied upon to assess the effectiveness, safety, or risk of a device. The FDA has noted an incr

    3/13/25 3:14:00 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    October 25, 2024 - FDA Roundup: October 25, 2024

    For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

    10/25/24 2:48:21 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for HYMPAVZI issued to PFIZER INC

    Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

    10/15/24 2:57:27 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMZN
    $PFE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight

    The alopecia areata market is expected to grow significantly as awareness of the condition increases, potentially expanding further in the coming years, supported by rising prevalence. Additionally, the launch of emerging therapies such as RINVOQ (AbbVie), Bempikibart (Q32 Bio), Coacillium (Legacy Healthcare), ALM 223 (Almirall), Amlitelimab (Sanofi), HCW9302 (HCW Biologics), ALY-101 (ALYS Pharmaceuticals), DR-01 (Dren Bio), Rezpegaldesleukin (Nektar Therapeutics), and others will further propel the market growth.LAS VEGAS, Feb. 19, 2026 /PRNewswire/ -- Recently published Alopecia Areata Market Insights report includes a comprehensive understanding of current treatment practices, alopecia ar

    2/19/26 5:31:00 PM ET
    $ABBV
    $HCWB
    $INCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch

    ViiV Healthcare's long-acting Cabenuva (cabotegravir + rilpivirine) for HIV demonstrates superior efficacy compared to daily oral therapy for people with adherence challenges; results published in NEJM

    Final data from LATITUDE study show switch to long-acting injectable treatment reduced the risk of virological failure by nearly half for study participants through 48 weeks, compared to those continuing on daily oral therapy ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced final data from the LATITUDE phase III trial, confirming its long-acting injectable treatment for HIV, Cabenuva (cabotegravir + rilpivirine), demonstrated superior efficacy in maintaining viral load suppression compared to daily oral therapy in individuals with a history of antiretroviral treatment (ART) adherence challenges.1 The 4

    2/18/26 5:00:00 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsight

    The juvenile idiopathic arthritis market is experiencing steady growth driven by rising disease awareness, improved diagnostic capabilities, and expanding access to advanced biologic therapies. Additionally, the launch of emerging therapies such as SOTYKTU (Bristol-Myers Squibb), BIMZELX (UCB Biopharma), MAS825 (Novartis), and others will further propel the market forward.LAS VEGAS, Feb. 17, 2026 /PRNewswire/ -- Recently published Juvenile Idiopathic Arthritis Market Insights report includes a comprehensive understanding of current treatment practices, juvenile idiopathic arthritis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036,

    2/17/26 5:31:00 PM ET
    $ABBV
    $BMY
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMZN
    $PFE
    Leadership Updates

    Live Leadership Updates

    View All

    Circana Appoints Highly Regarded Business Leaders to Board of Directors

    Chicago, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Circana LLC, a leading global provider of data, insights, and advisory services, today announced the appointment of three new members to its Board of Directors: Brian Cornell, Executive Chair of Target Corp.; Lauren Cooks Levitan, Co-Founder and Co-CEO of ROOT and Lead Independent Director at e.l.f. Beauty, Inc.; and Rohit Prasad, former Senior Vice President and Head Scientist of Artificial General Intelligence at Amazon.com, Inc. "These appointments strengthen the Board's ability to guide Circana's strategy and accelerate the value we deliver to our global clients," said Stuart Aitken, President and CEO of Circana. "We are focused on advancing

    2/11/26 8:00:00 AM ET
    $AMZN
    $TGT
    Catalog/Specialty Distribution
    Consumer Discretionary
    Department/Specialty Retail Stores

    Hasbro Announces Additions to Board of Directors

    Doug Bowser and Carla Vernón to join as newest Board members Today, Hasbro, Inc. (NASDAQ:HAS), a leading games, IP and toy company, announced that Doug Bowser, retired President and Chief Operating Officer of Nintendo of America Inc., and Carla Vernón, Chief Executive Officer of The Honest Company, Inc. have been appointed to Hasbro's Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120899535/en/ "We are delighted to have Doug and Carla join our seasoned and dynamic Board of Directors," said Rich Stoddart, Chair of Hasbro's Board of Directors. "Doug and Carla bring extensive leadership experience across co

    1/20/26 8:30:00 AM ET
    $AMZN
    $GIS
    $HAS
    Catalog/Specialty Distribution
    Consumer Discretionary
    Packaged Foods
    Consumer Staples

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    $AMZN
    $PFE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Amazon.com Inc.

    SC 13G/A - AMAZON COM INC (0001018724) (Subject)

    11/8/24 4:33:15 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Amazon.com Inc.

    SC 13G/A - AMAZON COM INC (0001018724) (Filed by)

    11/7/24 5:23:12 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    SEC Form SC 13G/A filed by Amazon.com Inc. (Amendment)

    SC 13G/A - AMAZON COM INC (0001018724) (Subject)

    2/13/24 4:55:57 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    $AMZN
    $PFE
    Financials

    Live finance-specific insights

    View All

    Amazon.com Announces Fourth Quarter Results

    Amazon.com, Inc. (NASDAQ:AMZN) today announced financial results for its fourth quarter ended December 31, 2025. Fourth Quarter 2025 Net sales increased 14% to $213.4 billion in the fourth quarter, compared with $187.8 billion in fourth quarter 2024. Excluding the $2.8 billion favorable impact from year-over-year changes in foreign exchange rates throughout the quarter, net sales increased 12% compared with fourth quarter 2024. North America segment sales increased 10% year-over-year to $127.1 billion. International segment sales increased 17% year-over-year to $50.7 billion, or increased 11% excluding changes in foreign exchange rates. AWS segment sales increased 24% year-over

    2/5/26 4:01:00 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance

    Focused Execution Drives Strong Full-Year 2025 EPS Performance Enters 2026 with Clear Strategic Priorities and Growing Late-Stage Pipeline Advanced 11 Key Pivotal Study Starts in 2025 and ~20 Key Pivotal Study Starts Planned for 2026 Pfizer Inc. (NYSE:PFE) reported financial results for fourth-quarter and full-year 2025 and reaffirmed its full-year 2026 financial guidance(1) provided on December 16, 2025. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: "With excellent execution in 2025, we delivered a solid financial performance and strengthened Pfizer's foundation for future growth. Looking ahead, 2026 will be an important year rich in key catalysts, inc

    2/3/26 6:45:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amazon.com to Webcast Fourth Quarter 2025 Financial Results Conference Call

    Amazon.com, Inc. (NASDAQ:AMZN) announced today that it will hold a conference call to discuss its fourth quarter 2025 financial results on Thursday, February 5, 2026, at 2:00 p.m. PT/5:00 p.m. ET. The event will be webcast live, and the audio and associated slides will be available for at least three months thereafter at www.amazon.com/ir. View source version on businesswire.com: https://www.businesswire.com/news/home/20260122132654/en/ Amazon.com Public Relations [email protected] amazon.com/ir

    1/22/26 4:01:00 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary